Chicago, Illinois and Natick, Massachusetts, November 11, 2020 – Proteintech and HebeCell announce
their collaborative partnership to develop proprietary nanobody based chimeric antigen receptor (nCAR)
technology for the development and commercialization of iPSC-derived natural killer (iPSC-nCAR-NK)
cells, a promising cellular immunotherapy treatment for cancer and other diseases.
Proteintech’s recent acquisition of nanobody manufacturer, ChromoTek, has made them a leading
player in the nanobody space. ChromoTek nanobodies are camelid single-chain recombinant affinity
reagents that fuel breakthrough research discoveries.
HebeCell holds unique expertise and intellectual property in induced pluripotent stem cells (iPSC) and
their lineage specific differentiation, especially toward natural killer (NK) cells. Although NK cells are
best known for killing virally infected cells, they also play key roles in detecting and controlling early
signs of cancer.
“Partnering with Proteintech will give both companies a competitive edge,” said Dr. Allen Feng, the
Founder and Chief Scientific Officer of HebeCell, “Our combined expertise and technologies create a
unique and special collaboration that will improve the treatment and care of cancer patients.”
Dr. Jason Li, CEO of Proteintech added, “I’ve known Dr. John Lu, Founder and CEO of HebeCell, for many
years and I’m glad we have an opportunity to work together on this important project. With HebeCell’s
proprietary NK cells and Proteintech’s nanobodies, the two companies can transform the future of
About Proteintech Group Inc.
Proteintech, founded in 2002, is a leading manufacturer of antibodies, proteins and immunoassays.
Proteintech has the largest proprietary portfolio of self-manufactured antibodies covering 2/3 of the
human proteome. With over 70,000 publications and confirmed specificity, Proteintech offers
antibodies and immunoassays across research areas. In addition, Proteintech produces cytokines,
growth factors and other proteins that are human expressed, bioactive and cGMP-grade. Proteintech
sites are ISO13485 and ISO9001-2015 accredited.
ChromoTek, recently acquired by Proteintech, is a pioneer in the development and commercialization of
innovative reagents based on camelid Nanobodies. In contrast to traditional antibodies, Nanobodies
consist of only one single polypeptide chain; they are the smallest known antibodies. The company has a
unique experience in the development of Nanobodies with desired affinities, specificities, and formats
for dedicated applications in biomedical research where other antibody formats fail. As a market and
product leader for high performing reagents, we are proud contributing to breakthrough research
discoveries around the world. In addition, ChromoTek is a trusted service provider of custom-made
Nanobodies for the pharmaceutical industry. Founded in 2008, ChromoTek has offices in Martinsried
(Germany) and Islandia (NY, USA).
About HebeCell Corporation
HebeCell, founded in 2016, focuses on the fields of Immunotherapy by developing human induced
pluripotent stem cell (iPSC)-based “off-the-shelf” CAR-natural killer (CAR-NK) and other immune cell
therapeutics targeting hematological malignancies and solid tumors, as well as autoimmune and
infectious diseases. HebeCell has expertise and assets in iPSC specific lineage cell differentiation and
state-of-the-art cGMP cell manufacturing facility. Its first-in-class proprietary 3D manufacturing platform
for human iPSC-CAR-NK cells is feeder-free and designed specifically for single-use-bioreactor at
industrial scale, which allows rapid deploy off-the-shelf CAR-NK cell products for all patients. HebeCell’s
platform technology will accelerate the application of iPSC cells as a viable source of immune cells in the
next generation of immunotherapy and will alter the CAR-NK cell therapy field by delivering cost
effective allogenic therapeutics worldwide.
Thompson + Conard Communications